Technical Analysis for FPRX - Five Prime Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 5.44 1.87% 0.10
FPRX closed up 1.87 percent on Thursday, September 19, 2019, on approximately normal volume. It ran into resistance at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FPRX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Spinning Top Other 0.00%
50 DMA Resistance Bearish 1.87%
Down 3 Days in a Row Weakness 1.87%
Down 4 Days in a Row Weakness 1.87%
Down 5 Days in a Row Weakness 1.87%
Lower Bollinger Band Touch Weakness 1.87%
20 DMA Resistance Bearish -0.91%
Fell Below 50 DMA Bearish -0.91%

Older signals for FPRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company's product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
Biotechnology Cancer Life Sciences Solid Tumors Monoclonal Antibodies Tyrosine Kinase Receptors Pfizer Glaxosmithkline Gastric Cancer Inflammatory Disease
Is FPRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.6
52 Week Low 4.885
Average Volume 274,547
200-Day Moving Average 9.0541
50-Day Moving Average 5.523
20-Day Moving Average 5.6235
10-Day Moving Average 5.722
Average True Range 0.3229
ADX 17.35
+DI 16.861
-DI 25.0094
Chandelier Exit (Long, 3 ATRs ) 5.4113
Chandelier Exit (Short, 3 ATRs ) 6.0887
Upper Bollinger Band 6.1306
Lower Bollinger Band 5.1164
Percent B (%b) 0.32
BandWidth 18.035032
MACD Line -0.0133
MACD Signal Line 0.0221
MACD Histogram -0.0354
Fundamentals Value
Market Cap 152.76 Million
Num Shares 28.1 Million
EPS -4.26
Price-to-Earnings (P/E) Ratio -1.28
Price-to-Sales 37.28
Price-to-Book 3.79
PEG Ratio 0.14
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.86
Resistance 3 (R3) 5.85 5.70 5.79
Resistance 2 (R2) 5.70 5.59 5.71 5.77
Resistance 1 (R1) 5.57 5.53 5.64 5.58 5.74
Pivot Point 5.42 5.42 5.45 5.43 5.42
Support 1 (S1) 5.29 5.31 5.36 5.30 5.14
Support 2 (S2) 5.14 5.25 5.15 5.11
Support 3 (S3) 5.01 5.14 5.09
Support 4 (S4) 5.02